Addex to Present at the 2025 Swiss Equities Baader Conference
08 1월 2025 - 3:00PM
Geneva, Switzerland, January 8, 2025
- Addex Therapeutics (SIX/NASDAQ: ADXN), a
clinical-stage biopharmaceutical company focused on developing a
portfolio of novel small molecule allosteric modulators for
neurological disorders, today announced that Dr Robert Lütjens,
Head of Discovery - Biology, will present at the Swiss Equities
Baader Conference being held in Bad Ragaz, Switzerland, January
08-10, 2025.
In his presentation, Dr Lütjens will provide a corporate update
and discuss recent advances from Addex’s CNS pipeline.
Presentation Details:Date: Friday, January 10,
2025Time: 11:40 CETConference Venue: Grand Resort Bad RagazRoom:
Forum 2
Dr Lütjens will be available for one-on-one
meetings throughout the conference. For more information or to
schedule a one-on-one meeting, please submit a request via the
Baader Conference portal or by sending an email
to IR@addexpharma.com. About Addex:
Addex Therapeutics is a clinical-stage
biopharmaceutical company focused on developing a portfolio of
novel small molecule allosteric modulators for neurological
disorders. Addex’s lead drug candidate, dipraglurant (mGlu5
negative allosteric modulator or NAM), is under evaluation for
future development in brain injury recovery, including post-stroke
and traumatic brain injury recovery. Addex’s partner, Indivior, has
selected a GABAB PAM drug candidate for development in substance
use disorders. Addex is advancing an independent GABAB PAM program
for chronic cough. Addex also holds a 20% equity interest in a
private company, Neurosterix LLC, which is advancing a portfolio of
allosteric modulator programs, including M4 PAM for schizophrenia,
mGlu7 NAM for mood disorders and mGlu2 NAM for mild neurocognitive
disorders. Addex shares are listed on the SIX Swiss Exchange and
American Depositary Shares representing its shares are listed on
the NASDAQ Capital Market, and trade under the ticker symbol “ADXN”
on each exchange. For more information,
visit www.addextherapeutics.com
Contacts:
| Tim DyerChief
Executive OfficerTelephone: +41 22 884 15
55PR@addextherapeutics.com |
Mike
SinclairPartner, Halsin Partners+44 7968
022075msinclair@halsin.com |
Addex Forward Looking
Statements:This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, as amended, including statements about the
intended use of proceeds of the offering. The words “may,” “will,”
“could,” “would,” “should,” “expect,” “plan,” “anticipate,”
“intend,” “believe,” “estimate,” “predict,” “project,” “potential,”
“continue,” “target” and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release, are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, uncertainties related
to market conditions. These and other risks and uncertainties are
described in greater detail in the section entitled “Risk Factors”
in Addex Therapeutics’ Annual Report on Form 20-F for the year
ended December 31, 2023, as filed with the SEC on April 18, 2024,
the final prospectus supplement and accompanying prospectus and
other filings that Addex Therapeutics may make with the SEC in the
future. Any forward-looking statements contained in this press
release represent Addex Therapeutics’ views only as of the date
hereof and should not be relied upon as representing its views as
of any subsequent date. Addex Therapeutics explicitly disclaims any
obligation to update any forward-looking statements.
Addex Therapeutics (NASDAQ:ADXN)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Addex Therapeutics (NASDAQ:ADXN)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
